Novelix Pharmaceuticals limited
(Formerly TRIMURTHI LIMITED) CIN: L67120TG1994PLC018956
(NOVELIX | 536565 | INE314I01036)

Date: 11th November, 2026

To,
The Deputy Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400001.

Sub: Statement of Deviation and Variation as per clause 32 (1), (2) and (3) for the quarter ended 30th September, 2026 under the SEBI (Listing Obligation and Disclosure Requirements), 2015.
Ref: Scrip Code: 536565
Scrip Id: NOVELIX

Dear Sir/Madam,

Please find enclosed herewith Statement of Deviation and Variation as per Clause 32(1) for the quarter ended 30th September, 2026 under the SEBI (Listing Obligation and Disclosure Requirements), 2015. The said statement was reviewed by Audit Committee and Board meeting held on 11th November, 2026.

Kindly acknowledge the same.

Thanking you

Yours sincerely,

For Novelix Pharmaceuticals Limited

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

STATEMENT OF DEVIATION OR VARIATION IN UTILISATION OF FUNDS RAISED
(Pursuant to Regulation 32(1), (2) and (3) of SEBI (LODR) Regulation 2015):1

Name of listed entity	Novelix Pharmaceuticals limited (Formerly Trimurthi Limited)
Mode of Fund Raising	~~Public Issues / Rights Issues /~~ Preferential ~~/ QIP / Others~~
Date of Raising Funds	09-07-2026
Amount Raised (Rs. In Lakhs)	506.25/-
Report filed for Quarter ended	30-09-2026
Monitoring Agency	N.A.
Monitoring Agency Name, if applicable	N.A.
Is there a Deviation /Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	N.A.
Explanation for the Deviation I Variation	N.A.
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments
Objects for which funds have been raised and where there has been a deviation, in the following table	

Original Object	**Modified Object, if Any**	**Original Allocation (Rs. In Lakhs)**	**Modified allocation, if any**	**Funds Utilized (Rs. In Lakhs)**	**Amount of Deviation/ Variation for the quarter according to applicable object**	**Remark**
To the object of meeting the long-term funding requirements of the Company including but not limited to working capital requirements and for general corporate purposes in order to support the future growth	N.A.	506.25/-	NIL	506.25/-	NIL	NIL

plan of the Company.						

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund-raising document.

For Novelix Pharmaceuticals Limited

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

STATEMENT OF DEVIATION OR VARIATION IN UTILISATION OF FUNDS RAISED
(Pursuant to Regulation 32(1), (2) and (3) of SEBI (LODR) Regulation 2015):2

Name of listed entity	Novelix Pharmaceuticals limited (Formerly Trimurthi Limited)
Mode of Fund Raising	~~Public Issues / Rights Issues /~~ Preferential ~~/ QIP / Others~~
Date of Raising Funds	09-07-2026
Amount Raised (Rs. In Lakhs)	684.00/-
Report filed for Quarter ended	30-09-2026
Monitoring Agency	N.A.
Monitoring Agency Name, if applicable	N.A.
Is there a Deviation /Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	N.A.
Explanation for the Deviation I Variation	N.A.
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments
Objects for which funds have been raised and where there has been a deviation, in the following table	

Original Object	Modified Object, if Any	Original Allocation (Rs. In Lakhs)	Modified allocation, if any	Funds Utilized (Rs. In Lakhs)	Amount of Deviation/Variation for the quarter according to applicable object	Remark
Lab Scale Tech Transfer Fee to GMBU, Germany	Nil	75.00	0.00	75.00	0.00	Nil
Deposit For Land Lease	Nil	100.00	0.00	100.00	0.00	Nil
Land Development	Nil	188.00	0.00	104.00	0.00	Nil
Consumables	Nil	100.00	0.00	100.00	0.00	Nil

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD

Travelling & Accommodation of German Tech	Nil	35.00	0.00	35.00	0.00	Nil
Pre Operative Expenses	Nil	125.00	0.00	125.00	0.00	Nil
Quality Control Equipments	Nil	61.00	0.00	61.00	0.00	Nil

Deviation or variation could mean:

(a) Deviation in the objects or purposes for which the funds have been raised or
(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
(c) Change in terms of a contract referred to in the fund-raising document.

For Novelix Pharmaceuticals Limited

Gnana Prakash Gattu
(Whole-time director)
DIN: 00517921

NOVELIX PHARMACEUTICALS LIMITED HYDERABAD